<DOC>
	<DOCNO>NCT00406107</DOCNO>
	<brief_summary>The purpose study evaluate effect intravitreal injection Macugen every 6 week treatment macular edema secondary branch retinal vein occlusion ( BRVO ) . We hypothesize macular edema secondary BRVO mediate VEGF 165 chronic suppression VEGF 165 successfully treat BRVO relate macular edema .</brief_summary>
	<brief_title>Evaluation Macugen Treatment Macular Edema Due Branch Retinal Vein Occlusion</brief_title>
	<detailed_description>Retinal venous occlusive disease , include central retinal vein occlusion ( CRVO ) branch retinal vein occlusion ( BRVO ) , second diabetic retinopathy cause vision loss due retinal disease . The main cause vision loss disorder development macular edema . Current clinical practice base randomize controlled clinical trial ( ETDRS , BVOS ) employ laser photocoagulation , either focal grid pattern , treat macular edema associate diabetic retinopathy branch retinal vein occlusion . Unfortunately , laser photocoagulation ineffective central retinal vein occlusion ( CRVO ) , proven therapy exist CRVO . The pathogenesis macular edema retinal vascular disease generally accept increased level vascular endothelial growth factor ( VEGF ) due ischemic stimulus . VEGF known one potent stimulators vascular leakage human . Therefore , seem sensible study inhibition VEGF reduce vascular leakage , reduce macular edema , improve vision retinal vascular disorder . Phase 2 randomize , control clinical trial Macugen diabetic macular edema macular edema associate CRVO conduct . In diabetes trial , patient treat Macugen improved vision , reduce macular edema measure optical coherence tomography ( OCT ) , reduce need laser treatment compare patient treat sham injection . In CRVO trial , patient treat Macugen 1 mg every 6 week 24 week improve vision reduce macular edema week 30 compare sham . This first randomized trial treatment CRVO show benefit control . Based positive finding , plan study Macugen treatment macular edema due BRVO .</detailed_description>
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Retinal Vein Occlusion</mesh_term>
	<criteria>Macular edema secondary BRVO involve foveal center male female patient least 18 year age Duration BRVO macular edema le 6 month prior baseline visit Best correct ETDRS visual acuity 20/4020/320 ( Snellen equivalent ) use 4 meter test method . Central foveal thickness great equal 250 micron use OCT3 Less 25 % foveal capillary ring disruption Less 2 disc area capillary nonperfusion within 1000 micron foveal center Absence hemorrhage lipid foveal center Investigator comfortable defer macular laser 18 week baseline intravitreous steroid 36 week baseline Ocular condition BRVO relate macular edema significant cataract , diabetic retinopathy , AMD , glaucoma , uveitis , epiretinal membrane , vitreomacular traction tumor . Intraocular surgery within past 3 month Significant enlargement foveal avascular zone ( &gt; 25 % disruption capillary ring ) great 2 disc area nonperfusion within 1000 micron foveal center . Likelihood evidence drive indication peripheral photocoagulation next 6 month . Patients show evidence spontaneous improvement within precede 3 month , determine improvement &gt; 15 letter vision thin Center Point OCT &gt; 20 % baseline determination Prior grid laser within 4 month baseline one prior grid laser treatment . No prior intravitreous periocular steroid injection study eye .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>branch retinal vein occlusion</keyword>
	<keyword>macular edema</keyword>
	<keyword>pegaptanib sodium</keyword>
	<keyword>vascular endothelial growth factor</keyword>
</DOC>